2023
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials
Loh J, Wu J, Chieng J, Chan A, Yong W, Sundar R, Lee S, Wong A, Lim J, Tan D, Soo R, Goh B, Tai B, Chee C. Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials. British Journal Of Cancer 2023, 128: 1514-1520. PMID: 36797357, PMCID: PMC10070409, DOI: 10.1038/s41416-023-02193-2.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsFemaleHumansLymphocytesNeutrophilsPatient SelectionPrognosisRetrospective StudiesTreatment OutcomeConceptsNeutrophil-lymphocyte ratioRoyal Marsden HospitalPhase I studyPhase I clinical trialPoor ECOG statusPre-treated patientsPrimary tumor sitePhase I populationLonger-term survivalECOG statusPrognostic factorsPrognostic scoreRetrospective reviewTumor siteAsian patientsSolid tumorsClinical outcomesPoor prognosisBackgroundPatient selectionPrognostic abilityPrognostic modelPatientsPrognosisIncreased scoresScores
2018
Biomarkers for Homologous Recombination Deficiency in Cancer
Hoppe M, Sundar R, Tan D, Jeyasekharan A. Biomarkers for Homologous Recombination Deficiency in Cancer. Journal Of The National Cancer Institute 2018, 110: 704-713. PMID: 29788099, DOI: 10.1093/jnci/djy085.Peer-Reviewed Original ResearchConceptsPoly-ADP-ribose polymeraseArray-based comparative genomic hybridizationSingle nucleotide polymorphismsHomologous recombination deficiencyPoly-ADP ribose polymerase inhibitorsComparative genomic hybridizationHomologous recombination genesNext-generation sequencingDNA repair pathwaysRecombination deficiencyClinical trialsGenomic hybridizationGermline BRCA1/2 mutation statusClinical development of PARP inhibitorsDefective DNA repairGenomic scarsResponse to platinum-based therapyHomologous recombinationDevelopment of PARP inhibitorsRecombinant genesNucleotide polymorphismsPlatinum-based therapyRibose polymeraseBRCA1/2 mutation statusDNA repair